诺唯赞子公司产品取得医疗器械注册证

Core Viewpoint - The company, NuoVance (688105.SH), has announced that its wholly-owned subsidiary, Nanjing NuoVance Medical Technology Co., Ltd., has obtained multiple medical device registration certificates for its series of diagnostic reagents for neurological systems, indicating market entry approval in China [1] Group 1: Product Development and Innovation - The company is leveraging its proprietary antibody technology platform to continuously enrich its Alzheimer's disease blood test series products based on global authoritative guidelines [1] - The focus is on developing innovative products for precise detection and diagnosis of major central nervous system diseases, including Parkinson's disease and brain injuries, addressing unmet clinical needs in the field of neurological diseases [1] Group 2: Strategic Goals and Market Impact - The company aims to enhance the product strength and influence of its chemiluminescence platform, contributing to the improvement of brain health and cognitive disorder diagnosis and treatment services in China [1] - The acquisition of these product registration certificates represents a significant step in actively implementing the "Healthy China Strategy" [1]